Symptoms
Common signs and symptoms of Lymphangioleiomyomatosis (LAM) include:
When to see a doctor
If you experience severe or worsening symptoms, seek immediate medical attention. Always consult with a healthcare professional for proper diagnosis and treatment.
Causes & Risk Factors
Several factors can contribute to Lymphangioleiomyomatosis (LAM).
Causes
LAM stems from mutations in genes that normally control cell growth and division. In most cases, the disease develops due to spontaneous mutations in the TSC1 or TSC2 genes, which produce proteins that act as cellular brakes to prevent uncontrolled growth. When these genes malfunction, cells begin growing and spreading abnormally throughout the lungs and lymphatic system. Think of these genes as traffic lights that have stopped working, allowing cellular traffic to move chaotically without proper regulation. In about 30-40% of cases, LAM occurs alongside tuberous sclerosis complex (TSC), an inherited condition passed down through families. When LAM develops as part of TSC, the genetic mutations are present from birth, though symptoms may not appear until adulthood. The remaining cases represent sporadic LAM, where the gene mutations occur randomly during a person's lifetime rather than being inherited. Research has shown that estrogen, the female hormone, can accelerate LAM progression, which explains why the disease predominantly affects women and why symptoms often worsen during pregnancy or with estrogen-containing medications.
Risk Factors
- Being female, especially of childbearing age
- Having tuberous sclerosis complex (TSC)
- Family history of tuberous sclerosis complex
- Pregnancy, which can accelerate disease progression
- Taking estrogen-containing medications or supplements
- Asian ancestry, which shows slightly higher prevalence
- Previous episodes of collapsed lung in young women
Diagnosis
How healthcare professionals diagnose Lymphangioleiomyomatosis (LAM):
- 1
Diagnostic Process
Diagnosing LAM often takes several years because early symptoms mimic common conditions like asthma or bronchitis. Most women visit multiple doctors before receiving the correct diagnosis, with the average delay ranging from 2 to 5 years after symptom onset. The diagnostic journey typically begins when a woman experiences repeated episodes of shortness of breath or a collapsed lung, prompting doctors to look beyond routine respiratory conditions. High-resolution computed tomography (HRCT) of the chest provides the most telling evidence, revealing characteristic thin-walled cysts scattered throughout both lungs like a honeycomb pattern. Doctors also measure levels of VEGF-D (vascular endothelial growth factor-D) in the blood, as this protein is typically elevated in women with LAM. Additional tests may include: - Pulmonary function tests to assess breathing capacity - Genetic testing for TSC1 and TSC2 mutations - Abdominal imaging to check for angiomyolipomas - Six-minute walk tests to evaluate exercise tolerance. The combination of typical lung cysts on CT scans, elevated VEGF-D levels, and characteristic symptoms usually confirms the diagnosis without requiring a lung biopsy.
Complications
- The most serious immediate complication of LAM is spontaneous pneumothorax, or collapsed lung, which affects up to 90% of women with this condition at some point.
- These episodes can occur suddenly without warning and may require emergency medical treatment, including chest tube insertion to re-expand the lung.
- Recurrent pneumothorax episodes often necessitate surgical procedures to prevent future occurrences.
- Progressive respiratory failure represents the most significant long-term complication, as the characteristic lung cysts gradually destroy healthy tissue and impair gas exchange.
- Many patients eventually require supplemental oxygen for daily activities and may need lung transplantation for survival.
- Angiomyolipomas, benign tumors that commonly develop in the kidneys of LAM patients, can grow large enough to cause pain or dangerous bleeding.
- These tumors require regular monitoring and sometimes intervention through embolization or surgical removal when they become problematic.
Prevention
- Since LAM results from genetic mutations that occur randomly or are inherited, primary prevention is not possible for most cases.
- However, women diagnosed with LAM can take steps to prevent complications and slow disease progression.
- Avoiding estrogen-containing medications, birth control pills, and hormone replacement therapy is crucial, as estrogen can accelerate the abnormal cell growth characteristic of LAM.
- Women with LAM should discuss pregnancy plans carefully with their healthcare team, as pregnancy can worsen the condition due to increased estrogen levels and physical demands on the lungs.
- Air travel requires special precautions, particularly avoiding flights during or shortly after pneumothorax episodes, as pressure changes can trigger lung collapse.
- - Avoid estrogen-containing medications and supplements - Discuss pregnancy risks and timing with doctors - Use caution with air travel, especially after lung collapse - Avoid activities with rapid altitude changes - Get prompt medical care for respiratory symptoms.
- While genetic counseling cannot prevent LAM itself, it helps families understand inheritance patterns, particularly for LAM associated with tuberous sclerosis complex.
Treatment
Currently, there is no cure for LAM, but several treatments can slow disease progression and manage symptoms effectively. Sirolimus (rapamycin) represents the primary medication for LAM, working to inhibit the abnormal cell growth that characterizes this condition. While sirolimus doesn't reverse existing lung damage, studies show it can stabilize lung function, reduce angiomyolipoma size, and improve quality of life for many patients. Most women taking sirolimus experience slower decline in breathing capacity compared to those not on treatment. Bronchodilators help open airways and improve breathing, while supplemental oxygen becomes necessary as the disease progresses. For severe cases, lung transplantation offers hope for extended survival, with many LAM patients successfully receiving single or double lung transplants. - Sirolimus therapy to slow disease progression - Bronchodilators for airway opening - Oxygen therapy as needed - Pulmonary rehabilitation programs - Treatment of angiomyolipomas if large or bleeding. Recent research has identified promising new treatments in clinical trials, including autophagy enhancers and anti-angiogenic therapies. Some patients benefit from participating in clinical studies testing novel approaches like stem cell therapies or targeted gene treatments, though these remain experimental.
Living With Lymphangioleiomyomatosis (LAM)
Living with LAM requires adaptations but doesn't mean giving up on an active, fulfilling life. Many women successfully manage careers, relationships, and family life while monitoring their condition closely. Regular exercise remains important, though activities may need modification as breathing capacity changes. Swimming, walking, and gentle yoga often work well, while activities involving altitude changes or risk of chest trauma should be avoided. Support groups, both in-person and online, provide invaluable connections with other women facing similar challenges. Building a strong healthcare team that includes pulmonologists familiar with LAM ensures optimal management and access to the latest treatments. - Maintain regular exercise within comfort levels - Connect with LAM support groups and organizations - Develop emergency action plans for pneumothorax episodes - Schedule regular monitoring appointments and tests - Stay informed about new treatments and clinical trials. The LAM Foundation and other organizations offer resources, research updates, and advocacy opportunities that help patients stay informed and hopeful. Many women with LAM find purpose in participating in research studies or fundraising efforts that advance understanding of this rare condition.
Latest Medical Developments
Latest medical developments are being researched.
Frequently Asked Questions
Update History
May 7, 2026v1.0.0
- Published by DiseaseDirectory